Prognostic and predictive immune gene signatures in breast cancer

Davide Bedognetti, Wouter R. Hendrickx, Francesco M. Marincola, Lance D. Miller

Research output: Contribution to journalReview article

34 Citations (Scopus)

Abstract

Purpose of review: Here, we focus on molecular biomarkers derived from transcriptomic studies to summarize the recent advances in our understanding of the mechanisms associated with differential prognosis and treatment outcome in breast cancer. Recent findings: Breast cancer is certainly immunogenic; yet it has been historically resistant to immunotherapy. In the past few years, refined immunotherapeutic manipulations have been shown to be effective in a significant proportion of cancer patients. For example, drugs targeting the PD-1 immune checkpoint have been proven to be an effective therapeutic approach in several solid tumors including melanoma and lung cancer. Very recently, the activity of such therapeutics has also been demonstrated in breast cancer patients. Pari passu with the development of novel immune modulators, the transcriptomic analysis of human tumors unveiled unexpected and paradoxical relationships between cancer cells and immune cells. Summary: This review examines our understanding of the molecular pathways associated with intratumoral immune response, which represents a critical step for the implementation of stratification strategies toward the development of personalized immunotherapy of breast cancer.

Original languageEnglish
Pages (from-to)433-444
Number of pages12
JournalCurrent Opinion in Oncology
Volume27
Issue number6
DOIs
Publication statusPublished - 9 Oct 2015

Fingerprint

Breast Neoplasms
Immunotherapy
Genes
Neoplasms
Drug Delivery Systems
Melanoma
Lung Neoplasms
Biomarkers
Therapeutics

Keywords

  • Breast cancer
  • Immune gene signatures
  • Immune score
  • Immunotherapy
  • Transcriptomic studies

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Prognostic and predictive immune gene signatures in breast cancer. / Bedognetti, Davide; Hendrickx, Wouter R.; Marincola, Francesco M.; Miller, Lance D.

In: Current Opinion in Oncology, Vol. 27, No. 6, 09.10.2015, p. 433-444.

Research output: Contribution to journalReview article

Bedognetti, Davide ; Hendrickx, Wouter R. ; Marincola, Francesco M. ; Miller, Lance D. / Prognostic and predictive immune gene signatures in breast cancer. In: Current Opinion in Oncology. 2015 ; Vol. 27, No. 6. pp. 433-444.
@article{3d4c959101774255b12027783df1e87b,
title = "Prognostic and predictive immune gene signatures in breast cancer",
abstract = "Purpose of review: Here, we focus on molecular biomarkers derived from transcriptomic studies to summarize the recent advances in our understanding of the mechanisms associated with differential prognosis and treatment outcome in breast cancer. Recent findings: Breast cancer is certainly immunogenic; yet it has been historically resistant to immunotherapy. In the past few years, refined immunotherapeutic manipulations have been shown to be effective in a significant proportion of cancer patients. For example, drugs targeting the PD-1 immune checkpoint have been proven to be an effective therapeutic approach in several solid tumors including melanoma and lung cancer. Very recently, the activity of such therapeutics has also been demonstrated in breast cancer patients. Pari passu with the development of novel immune modulators, the transcriptomic analysis of human tumors unveiled unexpected and paradoxical relationships between cancer cells and immune cells. Summary: This review examines our understanding of the molecular pathways associated with intratumoral immune response, which represents a critical step for the implementation of stratification strategies toward the development of personalized immunotherapy of breast cancer.",
keywords = "Breast cancer, Immune gene signatures, Immune score, Immunotherapy, Transcriptomic studies",
author = "Davide Bedognetti and Hendrickx, {Wouter R.} and Marincola, {Francesco M.} and Miller, {Lance D.}",
year = "2015",
month = "10",
day = "9",
doi = "10.1097/CCO.0000000000000234",
language = "English",
volume = "27",
pages = "433--444",
journal = "Current Opinion in Oncology",
issn = "1040-8746",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Prognostic and predictive immune gene signatures in breast cancer

AU - Bedognetti, Davide

AU - Hendrickx, Wouter R.

AU - Marincola, Francesco M.

AU - Miller, Lance D.

PY - 2015/10/9

Y1 - 2015/10/9

N2 - Purpose of review: Here, we focus on molecular biomarkers derived from transcriptomic studies to summarize the recent advances in our understanding of the mechanisms associated with differential prognosis and treatment outcome in breast cancer. Recent findings: Breast cancer is certainly immunogenic; yet it has been historically resistant to immunotherapy. In the past few years, refined immunotherapeutic manipulations have been shown to be effective in a significant proportion of cancer patients. For example, drugs targeting the PD-1 immune checkpoint have been proven to be an effective therapeutic approach in several solid tumors including melanoma and lung cancer. Very recently, the activity of such therapeutics has also been demonstrated in breast cancer patients. Pari passu with the development of novel immune modulators, the transcriptomic analysis of human tumors unveiled unexpected and paradoxical relationships between cancer cells and immune cells. Summary: This review examines our understanding of the molecular pathways associated with intratumoral immune response, which represents a critical step for the implementation of stratification strategies toward the development of personalized immunotherapy of breast cancer.

AB - Purpose of review: Here, we focus on molecular biomarkers derived from transcriptomic studies to summarize the recent advances in our understanding of the mechanisms associated with differential prognosis and treatment outcome in breast cancer. Recent findings: Breast cancer is certainly immunogenic; yet it has been historically resistant to immunotherapy. In the past few years, refined immunotherapeutic manipulations have been shown to be effective in a significant proportion of cancer patients. For example, drugs targeting the PD-1 immune checkpoint have been proven to be an effective therapeutic approach in several solid tumors including melanoma and lung cancer. Very recently, the activity of such therapeutics has also been demonstrated in breast cancer patients. Pari passu with the development of novel immune modulators, the transcriptomic analysis of human tumors unveiled unexpected and paradoxical relationships between cancer cells and immune cells. Summary: This review examines our understanding of the molecular pathways associated with intratumoral immune response, which represents a critical step for the implementation of stratification strategies toward the development of personalized immunotherapy of breast cancer.

KW - Breast cancer

KW - Immune gene signatures

KW - Immune score

KW - Immunotherapy

KW - Transcriptomic studies

UR - http://www.scopus.com/inward/record.url?scp=84944058907&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84944058907&partnerID=8YFLogxK

U2 - 10.1097/CCO.0000000000000234

DO - 10.1097/CCO.0000000000000234

M3 - Review article

VL - 27

SP - 433

EP - 444

JO - Current Opinion in Oncology

JF - Current Opinion in Oncology

SN - 1040-8746

IS - 6

ER -